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INTRODUCTION 
 Six years after the launch of the iPhone, it is almost impossible to 
conceive what our lives would be like without our mobile devices.1 And, 
regardless of your field of interest, chances are “there’s [at least] an app for 
that.”2 According to Portio Research, 1.2 billion people used mobile apps 
worldwide in 2012 and approximately 4.4 billion people will be using 
mobile apps by 2017. 3 While the total number of apps currently out on the 
market is hard to calculate, there are over 1,600,000 mobile apps only 
between Apple’s App Store and Google’s Play Store.4  
Mobile apps are no longer limited to games, but have also become 
players in fields such as education and medicine. The World Health 
Organization defines mobile health as “medical and public health practice 
supported by mobile devices, such as mobile phones, patient monitoring 
 
* Case Western Reserve University School of Law, JD 2015. I would like to thank 
Professor Raymond Ku and Professor Ruqaiijah Yearby for their guidance and 
encouragement, as well as the editors of JOLTI for their support during the 
publication process.  
1. See generally Olivia Williams, Why are we so frightened of NOT having a mobile 
phone?, DAILYMAIL Aug. 25, 2013, 4:05 PM, 
http://www.dailymail.co.uk/news/article-2401854/Why-frightened-NOT-having-
mobile-phone.html (suggesting that over half of the population may suffer from 
nomophobia: the fear of being without a mobile phone). 
2. THERE’S AN APP FOR THAT, Registration No. 4091498 (a trademark owned by 
Apple implying that for any task or purpose, there is an app for that task or 
purpose). 
3. MOBITHINKING, Global mobile statistics 2013 Section E: Mobile apps, app stores, 
pricing and failure rates, May 2013, http://mobithinking.com/mobile-marketing-
tools/latest-mobile-stats/e#appusers (citing a blog post from 
http://www.portioresearch.com/).  
4. Top iOS and Android apps largely absent on Windows Phone and BlackBerry 10, 
CANALYS (May 23, 2013), http://www.canalys.com/newsroom/top-ios-and-
android-apps-largely-absent-windows-phone-and-blackberry-10 (“[T]he Apple 
App Store and Google Play each boast more than 800,000 apps.”). 
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devices, personal digital assistants (PDAs), and other wireless devices.”5 
There are currently over 43,000 healthcare related apps in the iTunes store 
alone,6 and, according to Research2Guidance, 500 million people will be 
using healthcare mobile applications in 2015 globally.7  
This Note critiques the guidance document released by the Food and 
Drug Administration (“FDA”) in connection with the medical mobile apps 
it intends to regulate and the regulations that govern medical mobile apps. 
Specifically, the main argument of this Note is that, while the document is 
clearly a step in the right direction, significantly more guidance, focused on 
the characteristics of this new field, such as the rapid change of mobile 
technology, and on the transformational impact on healthcare of health IT 
in general and mHealth in particular, should follow soon. Part I provides an 
overview of the guidance document, with a focus on the FDA’s attempt to 
find the right balance between regulating apps that could potentially be 
harmful, and trying to promote innovation. Part II reviews the FDA 
regulations for medical devices in general, which the FDA used in its 
guidance document for medical mobile apps. Part III discusses ambiguities 
in the guidance document, the difficulties mobile app developers may 
encounter in trying to comply with it, the huge gap between the ability of 
conventional medical device manufacturers and that of medical mobile app 
manufacturers to go through the premarket approval process, and how the 
way the FDA intends to regulate medical mobile apps may ultimately 
impact innovation in the field. Part IV looks at potential solutions to 
improve the current regulations and strike the balance between ensuring 
safety and supporting innovation, and argues for a change in the way the 
FDA approaches regulation of mobile medical apps, which should 
incorporate a clear reflection of a field that is constantly evolving at a very 
fast pace, with very different players than the traditional medical device 
manufacturers, and for which a 40-year old framework is simply outdated. 
I. THE PROBLEM: MOBILE APPS AS MEDICAL DEVICES 
A. Mobile Apps. 
The Federal Food, Drug, and Cosmetic Act defines a medical device as 
“an instrument, apparatus, implement, machine, contrivance, implant, in 
vitro reagent, or other similar or related article, including any component, 
 
5. WORLD HEALTH ORG., MHEALTH: NEW HORIZONS FOR HEALTH THROUGH MOBILE 
TECHNOLOGIES (2011), available at 
http://whqlibdoc.who.int/publications/2011/9789241564250_eng.pdf.   
6. Press Release, IMS Institute for Healthcare Informatics, IMS Health Identifies 
Opportunities for Mobile Healthcare Apps to Drive Patient Engagement, Enhance 
Delivery of Care (Oct. 30, 2013), available at 
http://www.imshealth.com/portal/site/imshealth/ (follow “View All News” 
hyperlink, then navigate through list to “30 Oct 2013”).  
7. Ralf-Gordon Jahns, 500m people will be using healthcare mobile applications in 
2015, RESEARCH2GUIDANCE (Nov. 10, 2010), 
http://www.research2guidance.com/500m-people-will-be-using-healthcare-mobile-
applications-in-2015/. 
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part, or accessory, which is … intended for use in the diagnosis of disease 
or other conditions, or in the cure, mitigation, treatment, or prevention of 
disease, in man or other animals, or … intended to affect the structure or 
any function of the body.”8  
Before the world could even comprehend the idea of mobile apps as 
medical devices, the first mobile apps were built by handset manufacturers 
and carriers, and were part of the pre-installed software stack.  And while 
people who bought the same headset used to have the same exact device, 
no two people today have the same exact mobile phone because as soon as 
they get the device they are able to customize it based on their needs, 
interests and preferences.9  Nowadays, most of us also know someone who 
has built or is thinking about building an app. The change was driven by 
how mobile devices have evolved in terms of technology advancements, by 
manufacturers understanding the importance of giving access to the 
internal design of handsets, and by the emergence of proprietary platforms 
such as iOS and Android, on which developers can freely create apps not 
just for smartphones, but for a plethora of mobile devices.  With over “one 
billion active smartphones and tablets [currently being active] globally, … 
[analysts] expect [the number] to reach two billion in 2014.”10   
Using mobile health related apps was a natural progression for today’s 
consumers, who have been leveraging the Internet for years to look up 
medical information online. According to Pew Internet and America Life 
Project, 81% of American adults use the Internet, and 72% of Internet users 
looked online for health related information within the past year.11 As of 
April 2012, 19% of smartphone owners had downloaded an app 
specifically to track or manage health.12 We use our mobile devices to 
connect to our friends, our families, our business partners, so using them to 
connect to our healthcare providers and manage our health is only logical. 
As concluded by the GSM Association “[mHealth] solutions can help 
healthcare providers deliver better, more consistent, coordinated and more 
efficient healthcare, where and how it is needed, increase access to health 
services to remote or under-served communities and empower individuals 
 
8. Federal Food, Drug, and Cosmetic Act of 1938, 21 U.S.C. § 321 (2009).  
9. Gary Marshall, 10 Amazing Things You Never Knew a Smartphone Could Do, 
TECHRADAR (Aug. 26, 2013), http://www.techradar.com/us/news/phone-and-
communications/mobile-phones/10-amazing-things-you-never-knew-a-
smartphone-could-do-1175046 (“[M]anufacturers provide the hardware, and we 
turn them into magical machines with apps that transform them into musical 
instruments or games consoles, business machines or cat video players”). 
10. Mary Ellen Gordon, India, China and the Map to Two Billion Connected Devices, 
FLURRY (Jun. 10, 2013), http://blog.flurry.com/bid/97962/India-China-and-the-
Map-to-Two-Billion-Connected-Devices. 
11. Susannah Fox & Maeve Duggan, Health Online 2013, PEW INTERNET (Jan. 15, 
2013), http://www.pewinternet.org/~/media//Files/Reports/PIP_HealthOnline.pdf. 
12. Susannah Fox & Maeve Duggan, Mobile Health 2012, Pew Internet (Nov. 8, 
2012), http://www.pewinternet.org/files/old-
media//Files/Reports/2012/PIP_MobileHealth2012_FINAL.pdf.  
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to manage their own health more proactively and effectively.”13 By 2017, 
according to Research and Markets, half of the 3.4 billion smartphone or 
tablet users worldwide will use mobile health apps.14 
“[T]he use of mobile devices in the delivery of healthcare and  in 
obtaining healthcare knowledge [has become] ubiquitous.”15 In light of the 
Affordable Care Act, mobile devices are also one of the most promising 
tools in achieving an important goal of Accountable Care Organizations16, 
by reinforcing the best behavior in patients, reducing costs, and shifting the 
focus from just treatment to wellness and prevention. Mobile devices and 
the mobile apps they allow us to use are ideally suited to take healthcare 
outside of the hospital environment and begin a new age of remote 
medicine that has the potential to drive healthcare costs down while 
empowering the patients to become engaged in their health and wellness.  
In 2012, there were 828 companies in the high tech medical device 
industry, generating over $60 billion, and employing over 88,000 people,17 
and the top three companies (Medtronic, General Electric, and St. Jude 
Medical) controlled 32% of the market share.18 By contrast, according to 
the Wall Street Journal,19 the average app developer today is 29 years old 
or younger, 40% of app developers work alone, while 27% work at 2-3 
person firms, with 34% making less than $15,000 from app development, 
65% making less than $35,000, and only 12% making $100,000 or more. 
 
13. GSM ASS’N, mHealth and the EU Regulatory Framework for Medical Devices, 
http://www.gsma.com/connectedliving/wp-
content/uploads/2012/03/mHealth_Regulatory_medicaldevices_10_12.pdf (last 
visited Mar. 16, 2014). 
14. Erin McCann, MHealth Enters Consumer Golden Age, HEALTHCARE IT NEWS 
(Oct. 25, 2013), http://www.healthcareitnews.com/news/mhealth-enters-consumer-
golden-age.  
15. Paul De Muro, Mobile Medical Applications and the Affordable Care Act, THE 
LUND REPORT (Dec 2, 2013), http://www.thelundreport.org/content/mobile-
medical-applications-and-affordable-care-act (arguing that “[u]nder health reform, 
facilitated by the Affordable Care Act, (ACA) many can envision that 
mobile  medical apps will become increasingly important in this new patient-
centered care environment).  
16. American College of Physicians, Joint Principles for Accountable Care 
Organizations, , 
http://www.acponline.org/acp_policy/policies/joint_principles_accountable_care_o
rganizations_2010.pdf (last visited Mar. 16, 2014) (“Accountable Care 
Organizations must align mutual accountability at all levels, fostered by 
transparency and focused on health promotion and healthy development, disease 
prevention, care management, and care coordination”).  
17. Han Zhong, Primer: The Medical Device Industry (Jun. 2012), 
http://americanactionforum.org/sites/default/files/OHC_MedDevIndPrimer.pdf. 
18. Id.  
19. Scott Austin, The Surprising Numbers Behind Apps, Wall St. J., Mar. 11, 2013, 
http://blogs.wsj.com/digits/2013/03/11/the-surprising-numbers-behind-apps/. 
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B. FDA Guidance. 
On September 25, 2013, the FDA released its final guidance document 
pertaining to mobile medical apps it intends to regulate. While the FDA 
acknowledges that “[m]obile apps are unleashing amazing creativity, and 
[it] intend[s] to encourage these exciting innovations,”20 its guidance 
regarding mobile medical apps may slow down or deter the very innovation 
it intends to encourage. A summary of the guidance is provided below.    
Most analysts welcomed the newly released guidance, as it brought 
much needed clarity compared to the draft guidelines released by the FDA 
back in 2011.21 Morgan Reed, the executive director for the Association for 
Competitive Technology said that the new guidelines prove that the FDA 
“recognized that they aren’t going to tell us how to innovate.”22 In theory, 
this should be good news for app developers and for the industry in 
general. However, the FDA applied the same approach it used in regulating 
medical devices in general to medical mobile apps, which could prove 
problematic and counterproductive in the long run. Part III discusses this in 
detail.  
1. Apps That Are Not Medical Devices 
The apps included under this category are apps that “could be used in a 
healthcare environment, in clinical care or patient management, but are not 
considered medical devices.”23 Since these apps are not considered medical 
devices, the FDA will not regulate them. The list of examples included in 
the guidance document24 by the FDA indicates that the apps most likely to 
fall under this category are educational and informational, and are “not 
intended for use in the diagnosis of disease or other conditions, or in the 
cure, mitigation, treatment, or prevention of disease.”25 For example, these 
types of apps provide users and healthcare professionals with access to 
medical literature as well as commonly used reference information, can be 
training tools for healthcare providers, or help patients interact with their 
healthcare providers via different communications mechanism, as long as 
they are not intended specifically for medical use. If it simply informs or 
 
20. Keeping Up with Progress in Mobile Medical Apps, FDA CONSUMER HEALTH 
INFO. (FDA, Silver Spring, MD), Sept. 2013, at 2.  
21. Bradley Merrill Thompson, FDA (Finally) Returns Industry’s Calls for Mobile 
Medical Apps Guidance, MEDICAL DEVICE AND DIAGNOSTIC INDUSTRY ONLINE 
(Sep. 23, 2013), http://www.mddionline.com/blog/devicetalk/fda-finally-returns-
industrys-calls-mobile-medical-apps-guidance.  
22. Diana Manos, 3 Surprises in FDA’s Mobile Medical Apps Final Guidance, 
GOVERNMENT HEALTH IT (Nov. 6, 2013), http://www.govhealthit.com/news/3-
surprises-fdas-mobile-medical-apps-final-guidance. 
23. FDA, MOBILE MEDICAL APPLICATIONS GUIDANCE FOR INDUSTRY AND FOOD AND 
DRUG ADMINISTRATION STAFF, 2013 WL 5634256 at 12, (Sept. 25, 2013).  
24. Id. 
25. Id. 
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educates, a healthcare related mobile app is not considered a medical 
device, and the FDA will not regulate it.  
2. Apps That Are Medical Devices but over Which the FDA Will 
Exercise Enforcement Discretion 
In the case of apps that may be considered medical devices, but pose a 
low risk to patients, the FDA does not intend to enforce the requirements 
under the Food, Drug and Cosmetic Act.26 These types of apps go beyond 
information or education, and are mostly apps that allow patients to self-
manage their conditions, organize information related to their health, and 
communicate with their health care providers, as well as apps that automate 
simple tasks for health care providers.27 The key characteristic of the apps 
included in this category is that they do not provide “specific treatment or 
treatment suggestions.”28 Classified under this category are apps that track 
the user’s use of medication or medical devices, collect data from these 
medical devices (either electronically or data the use inputs manually), 
track health episodes such as asthma attacks and hospitalizations, and 
provide reminders and means to communicate with the user’s healthcare 
providers. In using the apps that fall under this category, the user is 
exposed to no risk or a minimal amount of risk, so the FDA will only 
exercise enforcement discretion. 
3. Apps That Are Medical Devices and over Which the FDA Will 
Exercise Regulatory Authority 
The FDA stated that it would focus its oversight on “medical mobile 
apps that meet the definition of device in the Federal Food, Drug and 
Cosmetic Act29 and are intended to transform a mobile device into a 
medical device regulated by the FDA, or be used as an accessory to a 
medical device regulated by the FDA.”30 The FDA explained that “[the] 
intended use of a mobile app determines whether it meets the definition of 
a ‘device.’”31 The intended use may be shown, for example, by “labeling 
claims, advertising matter, or oral or written statements by [the persons 
legally responsible for the labeling of devices], or by the circumstances that 
 
26. Id. at 16 
27. Id. 
28. Id.  
29. Federal Food, Drug, and Cosmetic Act of 1938, 21 U.S.C. § 321 (2009) (defining a 
medical device as “an instrument, apparatus, implement, machine, contrivance, 
implant, in vitro reagent, or other similar or related article, including any 
component, part, or accessory, which is … intended for use in the diagnosis of 
disease or other conditions, or in the cure, mitigation, treatment, or prevention of 
disease, in man or other animals, or intended to affect the structure or any function 
of the body of man or other animals ….”).  
30. FDA, MOBILE MEDICAL APPLICATIONS GUIDANCE FOR INDUSTRY AND FOOD AND 
DRUG ADMINISTRATION STAFF, 2013 WL 5634256 at 4, (Sept. 25, 2013). 
31. Id. 
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the article is, with the knowledge of such persons or their representatives, 
offered and used for a purpose for which it is neither labeled nor 
advertised.”32 Therefore, the FDA will consider a mobile app a medical 
device if it performs the functions of a medical device. If an app performs a 
medical function (diagnosing or recommending a treatment for example), 
then the app is a medical device and therefore subject to FDA’s oversight.  
In its guidance document, the FDA divided the types of medical 
mobile apps that will be subject to its oversight into three categories. 
Mobile apps that are extensions of a medical device are those mobile apps 
that connect to an existing medical device in order to control the device or 
display, analyze, or transmit patient-specific medical device data.33 Such an 
app would be, for example, a mobile app that controls the inflation and 
deflation of the blood pressure cuff of a traditional blood pressure monitor. 
Mobile apps that transform the mobile platform into a medical device 
through the use of attachments, sensors or display screens will be required 
to “comply with the device classification associated with the transformed 
platform.”34 Such an app would be, for example, a mobile app that 
performs the role of a blood glucose meter with a use of an attachment 
capable of reading blood glucose strips. Mobile apps that become a 
regulated medical device (software) by performing patient-specific 
analysis, providing diagnosis, or treatment recommendations are apps that 
are “similar to or perform the same function as those types of software 
devices that have been previously cleared or approved.”35 Such an app 
would be, for example, a mobile app that uses patient-specific parameters 
to calculate or create a dosage plan for radiation therapy.  
The FDA was responsive to the comments it received regarding the 
draft guidance published in July 2011, and, after collecting and analyzing 
input, it included multiple examples for each category,36 to help app 
manufacturers navigate the guidance document and identify which category 
their apps will fall under.37 In brief, the FDA will only regulate mobile 
apps that would qualify as medical devices, either on their own or in 
combination with an existent medical device. These apps will have to go 
through the same review system as the one the FDA has been employing 
for regular medical devices since 1976. Part II looks at the review system 
for medical devices.  
 
32. 21 C.F.R. § 801.4 (2007). 
33. FDA, supra note 30, at 8. 
34. Id. at 9. 
35. Id. 
36. FDA, supra note 20, at 1-2. 
37. Manos, supra note 22 (“[T]he guidance is chock full of anecdotes that provided 
better clarity”). 
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II. FDA REGULATIONS FOR MEDICAL DEVICES 
 The FDA has defined three classes of regulatory control for medical 
devices under the Federal Food, Drug, and Cosmetic Act.38 As indicated by 
the guidance document, mobile medical apps that will be subject to FDA’s 
oversight will be assigned to one of the same three classes described below.  
A. Class I 
 Medical devices classified under Class I are subject only to general 
controls.39 While general controls apply to all three classes, they are the 
only level of control that applies to medical devices in Class I. General 
controls for medical devices include device registration and listing, labeling 
requirements, records and reports, as well as good manufacturing 
practices.40 While general controls also include a requirement for 
premarket notification,41 FDA has exempted almost all Class I devices, 
with the exception of devices referred to as of Reserved Devices, from the 
premarket notification requirement.42 General controls also mean that the 
manufacturer has to abide by the good manufacturing practice (“GMP”) 
requirements set forth in Title 21 of the Code of Federal Regulations.43  
Mobile apps that qualify as Class I devices will thus be subjected to 
general controls alone, and the vast majority will be exempt from the 
premarket notification requirement. A premarket notification, also referred 
to as a 510(k), “is a premarketing submission made to FDA to demonstrate 
that the device to be marketed is safe and effective by proving substantial 
equivalence (SE) to a legally marketed device (predicate device) that is not 
subject to Premarket Approval (PMA).”44 The document issued by the 
FDA with regard to mobile medical applications lists premarket 
notification under general controls required for Class I devices, without 
 
38. 21 C.F.R. § 860.3(c) (2007). 
39. 21 C.F.R. § 860.3(c)(1) (2007) (“A device is in class I if (i) general controls are 
sufficient to provide reasonable assurance of the safety and effectiveness of the 
device, or (ii) there is insufficient information from which to determine that 
general controls are sufficient to provide reasonable assurance of the safety and 
effectiveness of the device or to establish special controls to provide such 
assurance, but the device is not life-supporting or life-sustaining or for a use which 
is of substantial importance in preventing impairment of human health, and which 
does not present a potential unreasonable risk of illness of injury”). 
40. FDA, General Controls for Medical Devices (May 13, 2009), 
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/Ge
neralandSpecialControls/ucm055910.htm.  
41. 21 C.F.R. § 807.81 (2007). 
42. FDA, Medical Device Exemptions 510(k) and GMP Requirements (Jan. 20, 2014), 
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/315.cfm. 
43. 21 C.F.R. § 820 (2007). 
44. FDA, How to Find a Predicate Device (Dec. 20, 2013), 
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarket
YourDevice/PremarketSubmissions/PremarketNotification510k/ucm134571.htm.  
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specifying the fact that most mobile medical apps that would be considered 
Class I devices would also be exempt from the premarket notification 
requirement.  
The only indication that the premarket notification for Class I devices 
may not be an absolute requirement is the fact that it is listed as a stand-
alone requirement for mobile medical apps in Class II.45 However, a 
medical mobile app in Class I may still be considered a reserved device, for 
which the premarket notification will not be waived. The FDA 
Modernization Act of 1997 explains in section 206 that “the exception … 
does not apply to any [C]lass I device that is intended for a use which is of 
substantial importance in preventing impairment of human health, or to any 
[C]lass I device that presents a potential unreasonable risk of illness or 
injury.”46 Such devices remain subject to premarket notification. The 
mobile app manufacturer must consult the list of reserved devices to make 
sure the mobile app does not require premarket notification. 
B. Class II 
 Medical devices classified under Class II are subject to general 
controls, special controls and premarket notification.47 Through the 
premarket notification, “[s]ubmitters must compare their 510(k) device to a 
similar legally marketed U.S. device.”48 The similar device is called a 
“predicate device,”49 and it can be a device that was marketed before May 
28, 1976, a device cleared under the 510(k), a device that was down-
classified from Class III to Class I or II, or a 510(k) exempt device.50 The 
predicate device does not have to be identical to the device in question. 
What the 510(k) must establish is substantial equivalence with the 
predicate device, which can be accomplished by analyzing the “intended 
use, design, energy used or delivered, materials, performance, safety, 
 
45. FDA, supra note 23, at 12. 
46. 21 U.S.C. § 360 (2009).  
47. 21 C.F.R. § 860.3 (2007) (“A device is in class II if general controls alone are 
insufficient to provide reasonable assurance of its safety and effectiveness and 
there is sufficient information to establish special controls, including the 
promulgation of performance standards, postmarket surveillance, patient registries, 
development and dissemination of guidance documents (including guidance on the 
submission of clinical data in premarket notification submissions in accordance 
with section 510(k) of the act), recommendations, and other appropriate actions as 
the Commissioner deems necessary to provide such assurance. For a device that is 
purported or represented to be for use in supporting or sustaining human life, the 
Commissioner shall examine and identify the special controls, if any, that are 
necessary to provide adequate assurance of safety and effectiveness and describe 
how such controls provide such assurance”). 
48. FDA, supra note 44. 
49. Id.  
50. Id.  
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effectiveness, labeling, biocompatibility, standards, and other applicable 
characteristics.”51 
 Grandfathered devices are those devices that were marketed prior to 
May 28, 1976, have not been significantly modified since then, and “for 
which a regulation requiring a premarket approval (PMA) application has 
not been published by FDA.”52  
C. Class III 
Medical devices classified under Class III are subject to premarket 
approval. These are the highest risk devices. Any new device that was not 
marketed before 1976 or that cannot claim substantial similarity with a 
predicate device is automatically a Class III device as well.53 This is 
regardless of the level of risk posed by the device. A wholly innovative 
device that addresses issues traditional devices did not or were not able to 
address, would thus be classified as Class III, simply because of its novelty, 
even if it poses no risk or a minimal amount of risk for the patient.  
Premarket approval is a great thing both for patients and for 
manufacturers.  It ensures patients are using a device that has been 
thoroughly tested and deemed safe by the FDA, and it shields 
manufacturers from legal action. In 2008, the Supreme Court in Riegel v. 
Medtronic stated that medical device manufacturers are immune from 
liability for personal injuries as long as the FDA approved the device 
before it was marketed and it meets the Agency’s specifications.54 The 
Supreme Court’s decision in Riegel does not impact devices that were 
approved through the 510(k) process, but only those that got FDA 
premarket approval.   
III. REGULATING MEDICAL APPS AS MEDICAL DEVICES 
A. Problems with the Current Regulation 
1. Mobile Apps as Class I Medical Devices 
For the average app developer, consulting and understanding the steps 
he/she needs to follow to determine whether the app he is building will be 
regulated or not, and what he needs to do to abide by the FDA regulations 
may not be so easy, despite the newly released guidelines.  Consider 
Breathometer, one of the first breathalyzers for smartphones. The portable 
device connects to any smartphone and “can transform your smartphone 
 
51. Id.  
52. Id.  
53. 21 C.F.R. § 860.3 (2007) (“A device is in class III if insufficient information exists 
to determine that general controls are sufficient to provide reasonable assurance of 
its safety and effectiveness or that application of special controls … would provide 
such assurance and if, in addition, the device is life-supporting or life-sustaining, 
or for a use which is of substantial importance in preventing impairment of human 
health, or if the device presents a potential unreasonable risk of illness or injury”). 
54. Riegel v. Medtronic, Inc., 552 U.S. 312 (2008).  
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into a breathalyzer within seconds — helping you monitor your alcohol 
consumption, giving you the power to make smarter decisions when 
drinking.”55 The keychain-sized device “plugs into the phone’s headphone 
jack and can connect to both Android and Apple apps [providing] … a way 
for people to check whether they’re too drunk to drive home.”56 
According to the FDA breath-alcohol test systems are medical 
devices.57 Breathometer qualifies as a medical app that will be the focus of 
FDA oversight. It is a mobile app that “transforms a mobile platform into a 
regulated medical device by using attachments, display screens, sensors, or 
other such methods.”58 Breathometer also qualifies as a Class I medical 
mobile app,59 subject to general controls, and it would also appear that it 
qualifies as a reserved medical device.60 Therefore, under the general 
controls specifications, Breathometer appears to be among the devices that 
are not exempted from the premarket notification requirement and will 
have to obtain the 510(k) clearance. Breathometer Inc. has registered 
Breathometer with the FDA, with the product code DJZ, which indicates 
under the “submission type” field that the device is subject to enforcement 
discretion.61  
There are two problems with how the guidelines for mobile medical 
apps apply to an app like Breathometer.  First, the guidance document for 
medical mobile apps specifies that for mobile apps for which FDA intends 
to exercise enforcement discretion, “the FDA intends not to pursue 
enforcement action for violations of the FD&C Act and applicable 
regulations by a manufacturer of a mobile app that meets the definition of a 
device in section 201(h) of the FD&C Act.”62 Thus, the app developer who 
sees Breathometer’s FDA submission could easily conclude that the FDA 
does not intend to pursue enforcement action for this category of mobile 
apps. Yet, a Breathalyzer is a Class I device, and the developer needs to 
comply with the general controls specified by the FDA. The app developer 
 
55. BREATHOMETER, https://www.breathometer.com/ (last visited Mar. 16, 2014).  
56. Jonah Cornstock, Six Attempts at a Smartphone-Connected Breathalyzer, 
MOBIHEALTHNEWS (Jun. 10, 2013), http://mobihealthnews.com/22907/six-
attempts-at-a-smartphone-connected-breathalyzer/4/. 
57. 21 C.F.R. § 862.3050 (2007) (“A breath-alcohol test system is a device intended to 
measure alcohol in the human breath. Measurements obtained by this device are 
used in the diagnosis of alcohol intoxication”). 
58. FDA, supra note 23, at 8. 
59. Id. 
60. FDA, Reserved Medical Devices (Jan. 20, 2014), 
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/3151.cfm. 
61. FDA, Product Classification (Jan. 20, 2014), 
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?ID=D
JZ. 
62. FDA, CHRH 1741, MOBILE MEDICAL APPLICATIONS GUIDANCE FOR INDUSTRY 
AND FOOD AND DRUG ADMINISTRATION STAFF, 2013 WL 5634256 at *7, n. 18 
(2013) [hereinafter MOBILE MEDICAL APPLICATIONS].  
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who wants to develop an app similar to Breathometer will likely be 
confused by the fact that the guidance document for medical mobile apps 
indicates that a mobile breathalyzer of this type would be the focus of the 
FDA’s regulatory oversight,63 while a search in the FDA’s database will 
reveal that the FDA seemingly only exercises enforcement discretion for 
medical devices with the product code DJZ.64  
The problem arises from the use of the term “enforcement discretion” 
by the FDA with two different meanings. In the first instance, as explained 
by the guidance document for medical mobile apps, enforcement discretion 
means that the FDA “does not intend to enforce requirements under the 
FD&C Act.”65 In the second instance, as used by the FDA under the DJZ 
product code, it means that the FDA will exercise enforcement discretion 
only with regards to the premarket notification requirement for some 
devices in Class I and Class II that qualify as “reserved devices.” While it 
appears that breathalyzers and other medical devices initially deemed 
“reserved devices” require 510(k) clearance, in December, 2011, the FDA 
released a guidance document instructing FDA staff that it intends the 
down-classification and exemption from the 510(k) requirement for a series 
of devices whose “safety and effectiveness … is sufficiently well 
established and they have sufficiently controlled risks that general controls 
are sufficient and a 510(k) review is not necessary.”66 Devices under 
product code DJZ were among those the FDA intends to take off the 
“reserved devices” list through an amendment.67 This confusion could lead 
the app developer to market his application, without complying with any of 
the general controls necessary for Class I, and thus violate the FDA’s 
guidance document for medical mobile apps. 
A second problem is that, while the FDA intends to exempt devices 
such as breathalyzers from the premarket notification requirement, the list 
of “reserved devices” on the FDA’s website still includes all the devices 
originally listed in the “reserved device” category, indicating that all the 
“reserved devices” have to comply with the premarket notification 
requirement. If the app developer chooses this venue of research, he will 
likely go through the 510(k) clearance process, despite the fact that the 
FDA no longer enforces it for this type of devices. Given the profile of the 
average developer,68 and the type of resources available to the average 
 
63. Id. at *9 (providing that apps which transform the mobile platform into a regulated 
device are amongst the focus of FDA regulatory oversight). 
64. FDA, Product Classification Database, supra note 61.  
65. FDA, MOBILE MEDICAL APPLICATIONS, supra note 62, at *10 (2013).  
66. FDA, Guidance for Industry and Food and Drug Administration Staff - 
Enforcement Policy for Premarket Notification Requirements for Certain In Vitro 
Diagnostic and Radiology Devices (Dec. 20, 2011), 
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDoc
uments/ucm283904.htm. 
67. Id.  
68. See supra Part I. 
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developer, this could either impose an unnecessary burden on the 
developer, or completely dissuade him from developing and marketing the 
app. 
The Breathometer/breathalyzer example illustrates an instance where 
the information in the guidance document for medical mobile apps is 
insufficient and can lead the app manufacturer, who is the ultimate 
recipient of the document, to either waste resources or ignore the FDA’s 
requirements for the class of devices the app belongs to. The inconsistency 
of the term “enforcement discretion” and the lack of clarity in the newly 
released guidance document for medical mobile apps can thus lead to 
undesirable results that can ultimately discourage innovation. In the 
example of the mobile Breathalyzer, if the information provided by the 
FDA in the guidance document and on its website were consistent and 
clear, the general controls required under Class I should be fairly easily 
complied with by any app manufacturer. The system is more complicated 
for Class II devices, for which “general controls alone are insufficient to 
provide reasonable assurance of [their] safety and effectiveness.”69 
2. Mobile Apps as Class II Medical Devices 
Mobile medical apps such as an electronic stethoscope or an ECG 
controlled through a mobile device would be classified as Class II 
devices.70 The manufacturers of the apps would thus have to go through the 
510(k) clearance process before they are able to market the mobile medical 
apps. And while the process has been in place for a while and may appear 
to be streamlined for traditional medical devices, the same may not be true 
for mobile medical apps. Given the various new parameters mobile devices 
are able to track and use (such as location, spatial positioning, and a whole 
set of data that they can obtain in real time by connecting to the Internet 
wherever the user may be), the manufacturers of medical mobile apps that 
can incorporate and take advantage of them will likely not be able to easily 
find a predicate device. The process is lengthy, difficult, and expensive, 
and substantial similarity, while not requiring an identical device, can be 
difficult to prove.  
A 2010 study by Stanford University and the National Venture Capital 
Association showed that “the average total cost … to bring a low- to 
moderate-risk 510(k) product from concept to clearance was approximately 
$31 million, with $24 million spent on FDA dependent and/or related 
activities.”71 For the traditional medical device manufacturer, big 
companies like Phillips or Omron, this would be part of the cost of doing 
 
69. 21 C.F.R. § 860.3 (2007).  
70. FDA, MOBILE MEDICAL APPLICATIONS, supra note 62, at *10 (2013). 
71. Josh Makower, Aabed Meer & Lyn Denend, FDA Impact on U.S. Medical 
Technology Innovation, NATIONAL VENTURE CAPITAL ASSOCIATION, at 28, Nov. 
2010, available at 
http://www.eucomed.org/uploads/Press%20Releases/FDA%20impact%20on%20U
.S.%20Medical%20Technology%20Innovation.pdf.  
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business. But going back to the average app developer, this is unattainable 
for most, and improbable even if they manage to secure investment. 
According to a report by research-focused investment bank Rutberg & 
Company, between January and August 2013, fifty companies in mHealth 
have managed to attract venture capital funding of $310 million72, a 
significant increase from the same period in 2012. Still, this averages 
approximately $6 million per company, a number that is nowhere close to 
the expenses estimated by Stanford in connection with getting the FDA’s 
510(k) clearance. While acknowledging the tremendous innovation that 
comes from startups in this field, Rajiv Chand, Managing Directors and 
Head of Research at Rutberg & Company cautions “that it is very difficult 
to grow companies within the sector and that although several companies 
are emerging as breakout leaders, most are struggling with adoption and/or 
revenue growth.”73 
Even considering that the financial obstacle could be surpassed, 
demonstrating substantial similarity could prove as much of a hurdle in the 
case of mobile medical apps. In a field that is constantly changing, time is 
of the essence. And the 510(k) can not only be a very difficult process, but 
it can also stretch past the 90 days the FDA estimates are necessary to 
determine substantial equivalency. 74  
MIM, the first mobile medical app to get FDA approval,75 provides the 
perfect example. It took the company two and a half years to get FDA 
510(k) clearance for an iOS viewer for CT and MRI images.76 While the 
company had gone through the 510(k) process before for different non-
mobile devices, without any difficulties, tackling the 510(k) for a mobile 
medical device proved to be a different story.77 Not only did the FDA close 
the company’s submission for lack of “substantial equivalence to a 
predicate device,” although the company had used as predicate device one 
of their own viewing software,78 but the app “got bumped up to Class 3 
Premarket Approval which is the same classification as high risk devices, 
 
72. Greg Slabodkin, VC Investment in mHealth Surpasses Last Year, FIERCE MOBILE 
HEALTHCARE (Sep. 27, 2013), http://www.fiercemobilehealthcare.com/story/vc-
investment-mhealth-surpasses-last-year/2013-09-27. 
73. Id.  
74. FDA, Premarket Notification (510k), 
http://www.fda.gov/medicaldevices/deviceregulationandguidance/howtomarketyou
rdevice/premarketsubmissions/premarketnotification510k/default.htm (last visited 
Mar. 6, 2015).  
75. Felasfa Wodajo, How the iPad radiology app MobileMIM became the first to get 
FDA approval: Interview with CTO Mark Cain, iMEDICALAPPS (Apr. 11, 2011), 
http://www.imedicalapps.com/2011/04/how-the-ipad-radiology-app-mobilemim-
became-the-first-to-get-fda-approval-interview-with-cto-mark-cain/. 
76. Id.  
77. Id.  
78. Id.  
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like implants.”79 The company resubmitted the 510(k) application, worked 
towards addressing the FDA’s concerns, and eventually got the FDA 
clearance a year and a half after resubmitting. While interoperability and 
wide reach are essential in mHealth, the manufacturers of MIM decided to 
stick with iOS and not release an Android version as well, despite the fact 
that Android currently dominates the market.80 The decision was based on 
how difficult it was to get FDA clearance for the iOS app, and “it became a 
time and resource issue.”81 
Over the past ten years, the FDA has cleared about 100 mobile apps 
through the 510(k) process,82 and according to the FDA it has taken on 
average 67 days for an app to get clearance. 83 This seems to be good news, 
given that the time for clearance was almost 30 days below the estimated 
90 days, but the FDA does point out that the duration of the clearance 
process “depends on the complexity and functionality of the app.”84 While 
these numbers are encouraging at first sight, Stanford’s survey points out 
that technology companies in the US have experienced on average a wait 
time between 10 and 31 months to obtain the 510(k) clearance.85 
Mobile devices have brought about a variety of exciting new 
possibilities for patient care and wellness, but new can also be problematic 
in terms of conquering the 510(k).  Introducing whole new functions that 
were not available on a predicate device, such as monitoring parameters in 
the user’s proximity, and taking them into account when giving the user 
feedback, can make it difficult for the app manufacturer to be able to claim 
substantial similarity with an existent predicate device. This also means, as 
proven by MIM’s example, that many app developers could find 
themselves walking a very fine line between having their device classified 
as a Class II or Class III device, not because of a high-risk app, but because 
of the novelty of the app’s features and capabilities.  
3. Mobile Apps as Class III Medical Devices 
Premarket approval (PMA) is the answer to a better, safer device. The 
overarching approach applied for medical devices in general encourages 
the right behavior, but there is a caveat. It only “speaks” to the traditional 
 
79. Id.  
80. Tony Bradley, Android Dominates Market Share, But Apple Makes All The Money, 
FORBES (NOV. 15, 2013), 
http://www.forbes.com/sites/tonybradley/2013/11/15/android-dominates-market-
share-but-apple-makes-all-the-money/.  
81. Wodajo, supra note 75. 
82. Carolyn Wang, FDA Mobile Medical App Tweetchat: #FDA #YayMe, WCG 
WORLD (Sep. 26, 2013), http://blog.wcgworld.com/2013/09/fda-mobile-medical-
app-tweetchat-fda-yayme. 
83. Id.  
84. Id.  
85. Makower, supra note 71, at 22.  
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manufacturer of medical devices – the big corporations such as Medtronic, 
Phillips etc. While especially in light of the Supreme Court’s decision in 
Riegel, medical device manufacturers are encouraged to go after premarket 
approval, the process is complicated and expensive. As part of the 
premarket approval process, manufacturers are required to submit clinical 
data supporting the application and the process of gathering this data 
requires the types of financial and logistic resources that the average app 
developer does not possess.  
Getting PMA approval is a time consuming process, which can be a 
major obstacle for a technology company. According to Stanford 
University’s study, while the FDA reported PMA review time is 9 months, 
it took survey participants on average 54 months to obtain PMA approval 
from the FDA.86 According to the same study, “the average total cost from 
concept to approval [for a PMA] was $94 million, with $75 million spent 
on stages linked to the FDA.”87 
By definition, Class III equals innovation – any new device that has 
not been marketed and does not have a predicate device would be classified 
as a Class III device. It also provides the ideal scenario for a business to be 
innovative – innovation will be rewarded once the device obtains the 
premarket approval and becomes immune to legal action for personal 
injury, which has put a huge number of manufacturers out of business (see 
silicone implants, or facial prosthetics in the 1980s and 1990s).88 But 
companies leading the space of traditional medical devices are large 
corporations. Any start-up that develops mHealth apps would probably 
love to go after premarket approval and benefit from the protection offered 
by the decision of the Supreme Court in Riegel, but the vast majority 
simply cannot. For the average app developer, premarket approval is a 
prohibitive process and, in virtually all situations, not a real option.  
B. Effects of FDA Regulation on Innovation 
While the FDA stated that it intends to foster innovation in the 
promising field of medical mobile apps, the guidance regarding mobile 
apps does not live up to that goal. It is great news that the FDA does not 
intend to regulate certain types of health related mobile apps, but the 
document it released in September 2013 applies a medical device “cookie-
cutter” approach to mobile medical apps, which is hardly the type of 
solution that will encourage app developers to innovate. As history proves, 
many times it is not big corporations that drive innovation, but start-ups. 
Microsoft, Apple and Google were all started by a handful of people in a 
garage office. The game-changers in the field of mobile medical apps can 
be anybody from a computer-science college student, to a doctor, or a small 
 
86. Id. at 23. 
87. Id. at 28. 
88. Charles A. Homsey, How FDA Regulation and Injury Litigation Cripple the 
Medical Device Industry, CATO Institute, Aug. 28, 2001, available at http:// 
www.cato.org/pubs/pas/pa412.pdf. 
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company with a couple of employees. Almost none of these app developers 
would have the necessary resources to go through the lengthy and 
exorbitant premarket approval process. 
Mobile medical apps would likely be classified as a Class III device 
simply because of the degree of innovation manufacturers are able to 
incorporate, not because they are all life-threatening devices. A mobile app 
that would control a pacemaker, or other implantable devices, would most 
likely qualify as a Class III device and would have to undergo the PMA 
process. But what should qualify a mobile medical app as a Class III device 
should only be the level of risk to patients, not its sheer novelty. In the 
current approach employed by the FDA, which “emphasizes risk over 
benefit,”89 a mobile medical app that would perform the features of a blood 
pressure monitor, and therefore could go the 510(k) route, but that can also 
take into account parameters such as humidity, temperature, altitude, and 
activity level when analyzing the results of your blood pressure readings, 
would likely have to go through the PMA process. Just because a predicate 
device couldn’t employ these features at the time, should not be reason 
enough to delay the timely development of such medical mobile apps that 
would not only be an incredible improvement on existent traditional 
medical devices, but could also provide patients with vital life-saving 
information in a timely manner. What are the consequences if there is no 
change? App developers would either be tempted to cut features, so they 
could go after the 510(k) clearance and avoid the PMA, or not develop the 
medical app at all, as the PMA would appear as an insurmountable hurdle. 
The end user is the one who stands to lose the most.  
 In an interview with the Baltimore Sun, Chris Bergstrom, Chief 
Strategy and Commercial Officer with mobile medical app developer 
WellDoc, pointed out that developers will have to decide “whether they 
want to seek FDA approval for something that will diagnose or help treat a 
disease, of if they will develop something geared towards entertainment 
and wellness.”90 Similarly, Orrin Franko, doctor, app developer and 
founder of the Journal of Mobile Technology in Medicine, told USA Today 
that “app developers with products that are not strictly medical … may 
avoid making medical claims in their marketing in order to skip the FDA 
process.”91 The financial incentives are pointing developers away from 
 
89. Sharon Stevenson, Managing Director Okapi Venture Capital, Testimony on the 
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Mobile Medical Apps, The Baltimore Sun, Sep. 23, 2013, 
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going after FDA approval, as “going from zero to mobile application is 
often not the most straightforward, or even worthwhile, road.”92  
 Technology is fast moving and the FDA is historically the opposite of 
that. That is one of the reasons that created the confusion regarding 
enforcement discretion and how it would apply in the case of breathalyzers 
discussed in Part II.93 The initial draft released by the FDA in 2011 brought 
more confusion than clarity.94 The agency did manage to clarify some of 
the confusion with the newly released document (it clarified FN 13 that 
referred to apps over which FDA would exercise enforcement discretion as 
mobile medical apps; it provided more examples for each category of apps, 
and changed its opinion regarding some apps that perform basic clinical 
analysis such as an Apgar score app, which under the draft guidance would 
have been regulated, but under the final guidance document will not).95 
However, it took the FDA two years to come up with the final document, 
and the biggest flaw of the document is that it treats apps as it would 
traditional medical devices, without taking into account the particularities 
of the industry. 
 Mobile medical app developers spoke before the House Subcommittee 
on Health and Technology in June 2013 about the obstacles they face, 
especially from a regulatory standpoint, warning Congress that “[w]ith the 
possibility of unintended consequences disproportionately affecting small 
businesses, it’s important for Congress to move carefully when making 
changes that affect health care mobile technologies.”96 As the final  
91. Jenny Gold, FDA Regulators Face Daunting Task as Health Apps Multiply, USA 
Today, Jun. 27, 2012, http://usatoday30.usatoday.com/news/health/story/2012-06-
22/health-apps-regulation/55766260/1 (explaining the difficulties of monitoring 
health apps and developing guidelines thereof faced by the FDA).. 
92. Chris Wiltz, Pick a Good Problem: Mobisante's Approach to Mobile Health, 
MOBILE DEVICE AND DIAGNOSTIC INDUSTRY ONLINE (Nov. 5, 2013), 
http://www.mddionline.com/article/pick-good-problem-mobisantes-approach-
mobile-health (providing author’s suggestion for developing an mHealth 
application or device within the small space granted by the FDA). 
93. The decision to take a number of devices off the reserved devices list was reached 
in 2011, but it still hasn’t been made the law, which explains why all those devices 
still appear on the reserved list indicating that 510(k) clearance is required. 
94. Scott D. Danzis & Christopher Pruitt, Rethinking the FDA's Regulation of Mobile 
Medical Apps, 9 THE SCITECH LAWYER, no. 3, 2013, at 26, 
http://www.cov.com/files/Publication/56c8d97e-4432-4623-b81c-
1230545cc204/Presentation/PublicationAttachment/cb8b13fe-9b8f-4de4-b8d3-
15096d3b25be/Rethinking_the_FDA’s_Regulation_of_Mobile_Medical_Apps.pdf 
(describing the FDA’s historic policies on software and puts forth draft guidance 
on mobile medical apps, suggesting a balance regulatory approach). 
95. Id.  
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MOBILE DEVICE AND DIAGNOSTIC INDUSTRY ONLINE (Jul. 2, 2013), 
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document had not been released yet, the small business representatives 
stressed during the same meeting the “immediate need for clear, 
comprehensive FDA guidance.”97 Once the document was released, health 
IT groups welcomed it, but also pointed out its flaws.  
Joel White, Executive Director of the Health IT Now Coalition, 
explained that “many app developers are not opposed to regulation, but 
they believe the FDA process, [which was created when the floppy disk 
was around,] doesn’t fit the industry.”98 The Health IT Now Coalition 
stated in a news release that the FDA “endorsed an old framework,”99 and 
that “the administration and Congress ought to work together on updating 
the 1970s era law to meet the needs of the 2013 … mobile health 
community.”100 
 The mHealth Regulatory Coalition, while welcoming the much-needed 
FDA guidance, pointed out that “the final guidance is fundamentally like 
the proposed guidance [of 2011], and omits some very important areas.”101 
Members of the Digital Health Coalition voiced the same concerns. Marc 
Monseau, Managing Partner with Mint Collective referred to the questions 
left unanswered by the document, “[in] particular, … [the lack of] a precise 
definition of which app will be regulated, [and] … the exact meaning of an 
accessory to a medical device.”102 Robert Palmer, Managing Partner with 
Juice Pharma Worldwide, expressed the same concerns that seem to 
pervade the mobile medical app field: “potential unintended consequences 
that could inhibit innovation and add to the time and expense of bringing 
new apps to market.”103 
A lot of questions still remain. What happens when the manufacturer 
of a completely new medical mobile app obtains premarket approval, and 
then releases an update to the app? Does he have to get a 510(k) clearance 
for every update? What if the new update introduces completely new 
features that impact the ability to claim substantial similarity? Even when 
referring to software updates to traditional medical devices, the FDA 
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seemed to indicate that it is difficult to say when a new 510(k) is 
needed.104Mobile apps are different. Frequent updates are a staple of any 
existing mobile app. Updates are not triggered just by the constant 
advancement of technology in the field of mobile devices, but also by the 
ease with which a mobile app can be modified and updated. Traditionally, a 
modification in a medical device is a process that can take years, while  a 
developer can change a mobile app in a matter of hours. Mobile apps are 
“updated and created on a daily basis, …[and the] lifecycle [of a mobile 
app] is dramatically different.”105 
 Treating health-related mobile apps the same as medical devices 
hampers app developers in the US and foreign app developers who would 
like to enter the US market. In the end, by blocking or delaying innovation, 
the ones who will suffer the most will be US consumers. But the Internet 
provides patients with access to apps that the FDA does not reach. This is a 
high risk, both for consumers and app developers. Where app developers 
outside the reach of the FDA become the main provider of mHealth 
solutions for US patients, and patients end up using apps that are 
potentially not subject to any kind of safety regulation, consumer safety is a 
big issue. At the same time, the FDA’s slow response time, lack of 
transparency, and its increasingly risk-averse attitude towards new 
products,106 makes it more difficult for US producers to compete with 
foreign producers, and provides incentives for US companies to launch and 
market their apps on foreign markets for a quicker and safer return on 
investment.  
While testifying in front of the U.S. House of Representatives in 
September 2011, Sharon Stevenson, on behalf of the National Venture 
Capital Association, emphasized that as a consequence of growing 
regulatory challenges “[w]e are seeing [investors] moving away from [life 
sciences companies] … [and] sending private investment dollars previously 
dedicated to U.S. companies to start ups overseas, or [making plans] to 
commercialize their products outside of the U.S., …as genuine ongoing 
businesses.”107 Stevenson cited “the uncertain regulatory environment of 
the FDA”108 as the number one factor contributing to the decrease in 
venture capital investments in the development of new therapies and 
technologies related to life sciences. The lack of available funding in life 
sciences has had a significant impact on biotechnology startups especially, 
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uments/ucm080235.htm (“The major difficulty lies in sorting out which of these 
changes is significant enough to trigger the need for a 510(k)”).  
105. Gold, supra note 91. 
106. Makower, supra note 71, at 24-25. 
107. See Stevenson, supra note 89. 
108. Id. 
Journal of Law, Technology & the Internet · Vol. 6 · 2015  
The FDA Guidance Documents for Medical Mobile Apps and its Impact on Innovation 
63 
which, like mobile app development companies, tend to have fewer 
resources than large players. As a direct consequence of the decline in 
venture capital investments, “[t]here were only 15 first-time biotech 
financings nationally in the third quarter of 2012, which continue[d] a year 
long decline.”109 Carl Weissman, the CEO of Accelerator, a venture-backed 
biotech incubator, called 2012 “the saddest period in biotech.”110 As 
exciting as the new field of mHealth is, if the regulatory hurdles 
discouraged investors from backing biotech companies, the same fate 
awaits mHealth players, who desperately need funding to be able to take on 
the “FDA challenge.”  
IV. SOLUTIONS 
 While the FDA was praised for not telling us how to innovate,111 the 
FDA has not told us nearly enough about health-related apps to reach the 
goal of both protecting consumers and supporting innovation. The guidance 
document should not just mimic the system used for medical devices. 
While the FDA has had a sinuous history in its attempt to regulate 
software,112 it cannot simply address this using a cookie-cutter approach. 
There is an argument that following the existing approach allows 
developers to at least consider how the FDA has treated medical devices in 
the past, and provided the FDA with a solution to keep its promise and 
deliver the final document before the end of 2013, the document in its 
current form should only be a temporary solution. It provided answers to 
some questions, it clarified some aspects that were not clearly defined in 
FDA’s 2011 attempt, and it was overall a positive move for the developer 
community that had dealt with a lot of uncertainty in the recent years, and 
more questions than answers. And while positive effects such as “more 
money, resources and energy devoted to the development of mobile 
apps,”113 will soon follow or have already started to show, the FDA will 
have to embrace and be able to reflect change in order to be able to keep its 
promise and encourage innovation.  
Some stakeholders have suggested that medical mobile apps should be 
treated as a separate new category with its own rules that take into account 
the realities of the software development industry. Joel White, executive 
director of the Health IT Now Coalition suggested that “the government set 
up a new regulatory framework for mobile health – something like the 
National Transportation Safety Board – to accommodate the speed, 
flexibility and innovation on this new marketplace.”114 Not everyone agrees 
 
109. Luke Timmerman, The Few and the Proud: The Biotech Startup Class of 2012, 
XCONOMY (Nov. 26, 2012), http://www.xconomy.com/national/2012/11/26/the-
few-and-the-proud-the-biotech-startup-class-of-2012/. 
110. Id.  
111. Manos, supra note 22. 
112. See generally Danzis, supra note 94.  
113. Digital Health Coalition, supra note 102. 
114. Gold, supra note 91.  
Journal of Law, Technology & the Internet · Vol. 6 · 2015  
The FDA Guidance Documents for Medical Mobile Apps and its Impact on Innovation 
64 
with this approach, though. In a white paper by Epstein Becker & Green, 
member of the mHealth Regulatory Coalition, the law firm argues that 
“[a]s technology and the marketplace move toward convergence, [it] would 
be a terrible time for regulation to move toward divergence.”115 However, 
there is no denying that health IT is changing the face of healthcare as we 
know it, and this change needs to be reflected in the regulatory framework 
fast.  
Before any structural change is implemented, a quick fix would be to 
elaborate in order to simplify, by expanding right away on the current 
guidance document and specifying which mobile medical apps would be 
considered Class II or Class III devices. The Agency should follow the 
same approach that was used to down-classify some medical device data 
systems from Class III to Class I116, in order to prevent the absurd situation 
where an innovative mobile medical app that poses no risk to patients 
would be classified as a Class III device by default because of its novelty 
and capabilities.  
As pointed out by the National Venture Capital Association, the 
“adoption of a more flexible benefit-risk paradigm [would allow for] 
differentiation in the level and amount of evidence required.”117 The 
NVCA also urges the FDA to adopt a “qualitative framework for benefit-
risk assessment … that incorporates robust input from stakeholders, 
including patients and consumers.”118 A more flexible risk-benefit 
paradigm would definitely have a positive impact on the approval process 
for mobile medical apps as well.  
Another option to speed up the process and support developers would 
be to implement new premarket approval requirements for mobile medical 
apps, which should be very different than the ones used for traditional 
medical devices. “[Developers] thrive in an environment in which change 
is constant …, and changing that culture and environment by imposing 
regulatory obligations that would dramatically lengthen the product 
lifecycle would have a tremendous stifling impact [on them].”119 This field, 
which is constantly changing and evolving, cannot be forced to fit 
successfully into a regulatory scheme created over 40 years ago. A 
possibility to try to close the gap would be to create a version of the 510(k) 
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that is more responsive to the needs and realities of this market, as well as 
implement a system similar to the Accredited Persons Program used to 
improve the efficiency and the timeliness of the 510(k),120 where the 
accredited partners would be centers that are able to test and approve the 
apps, in a simpler and faster manner than the premarket approval process 
used for medical devices. This is an exciting new field, and these are 
“transformational times in American health care,”121 which offer a great 
opportunity for the FDA to “take a decentralized for profit approach to 
mobile health application approval.”122  
Regardless of how it does it, the FDA will have to start implementing 
the kind of changes that prove it understands the extraordinary role it plays 
in the success of modern healthcare, which is more and more focused 
around e-health.  
CONCLUSION 
 The FDA guidance document for medical mobile apps is a step in the 
right direction that analysts welcomed. Nevertheless, the field of mHealth 
requires more guidance specifically tailored to respond to the needs of the 
players driving this field forward, and ultimately respond to the needs of 
the modern patient. The guidance document is still too ambiguous and the 
examples it includes are not enough to answer all the questions app 
developers might have regarding whether or not the FDA will regulate their 
apps. This ambiguity may ultimately lead to stifling the innovation the 
FDA wants to promote, through a self-policing process that, together with 
the limited resources available to the average mobile app developer, may 
result in an over-simplification of medical mobile apps or even in 
developers delaying or deciding not to develop complex medical mobile 
apps altogether, to the detriment of the end user.  
 While applying the same approach it took to regulating traditional 
medical devices to medical mobile apps offered the agency a fast solution 
to start the conversation about medical mobile apps, the FDA needs to 
continue this conversation by listening to all stakeholders, including 
doctors and patients, and working closely with other agencies, such as the 
FCC, to develop a coherent regulatory framework for mHealth, one that 
recognizes the significant differences between medical mobile apps and 
traditional medical devices. Working towards the goal of promoting 
innovation, while ensuring patient safety, the FDA should provide 
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developers not only with the proper regulatory framework, but also with 
the tools that would help them navigate it, and with solutions realistically 
tailored to put safe mHealth solutions in the hands of patients in the 
shortest time possible. Given the novelty of the field and the specific 
characteristics of mobile apps, the FDA should develop a platform focused 
on primarily assessing the risks related to medical mobile apps and create 
the premises to bring in entities with knowledge and expertise in the field 
of mHealth to evaluate and certify medical mobile apps in a manner that 
takes into account the realities of this new and exciting field. This would 
prevent situations where medical mobile apps that pose minimal or no risks 
to patients would be qualified as Class III medical devices simply because 
of the novelty of the features they incorporate, and would provide a 
solution that moves as fast as this new industry does, to the benefit of all 
players.    
 
 
 
 
 
 
